Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Combination Therapy for Oral Cancer: Current Trends and Challenges
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Combination Therapy for Oral Cancer: Current Trends and Challenges

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dentistry, Oral Surgery and Oral Medicine".

Deadline for manuscript submissions: closed (15 October 2024) | Viewed by 2199

Special Issue Editors

Dr. Yasumasa Kakei

E-Mail Website
Guest Editor
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Interests: oral squamous cell carcinoma; oral cancer; metastasis; tumor microenvironment
Dr. Takumi Hasegawa

E-Mail Website
Guest Editor
Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
Interests: oral squamous cell carcinoma; oral cancer; metastasis; tumor microenvironment

Special Issue Information

Dear Colleagues,

Oral cancer is a leading cause of cancer-related death worldwide. Conventional treatment strategies for oral cancer, such as surgery, chemotherapy, and radiation therapy, have made significant progress in improving survival rates. However, these treatments can also have significant side effects.

Combination therapy is an emerging approach to oral cancer treatment that combines two or more different therapies. This approach has the potential to improve efficacy and reduce side effects compared to single-modality therapy.

The current trends in combination therapy for oral cancer include the use of the following:

  • Targeted therapy: targeted therapy drugs work by targeting specific molecules involved in cancer growth and progression.
  • Immunotherapy: immunotherapy drugs work by boosting the body's immune system to fight cancer cells.
  • Radiation therapy: radiation therapy uses high-energy beams to kill cancer cells.

The challenges in combination therapy for oral cancer include the following:

  • Drug resistance: cancer cells can develop resistance to targeted therapy and immunotherapy drugs.
  • Toxicity: combination therapy can have more side effects than single-modality therapy.
  • Personalized treatment: the optimal combination of therapies may vary from patient to patient.

This Special Issue of the Journal of Clinical Medicine on combination therapy for oral cancer will bring together leading experts in the field to discuss the latest advances in this area. The articles in this Special Issue will provide valuable insights into the potential of combination therapy to improve the treatment of oral cancer.

Dr. Yasumasa Kakei
Dr. Takumi Hasegawa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral cancer
  • oral squamous cell carcinoma
  • oral melanoma
  • combination therapy
  • targeted therapy
  • radiation therapy
  • drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1266 KiB  
Article
A Study of the Prognostic Factors for Late Cervical Lymph Node Metastasis and Distant Metastasis in Patients with cT1-2N0 Tongue Cancer
by Fumitaka Obayashi, Koichi Koizumi, Nanako Ito, Mirai Higaki, Yasutaka Ishida, Atsuko Hamada, Sachiko Yamasaki, Ryouji Tani and Souichi Yanamoto
J. Clin. Med. 2024, 13(4), 976; https://doi.org/10.3390/jcm13040976 - 8 Feb 2024
Cited by 2 | Viewed by 1667
Abstract
Background: Early-stage tongue cancer has a good prognosis in general; however, high-risk patients with late cervical lymph node and distant metastases have a poor prognosis. Elective neck dissection and postoperative chemoradiotherapy are considered for these patients, although no clear criteria have been identified [...] Read more.
Background: Early-stage tongue cancer has a good prognosis in general; however, high-risk patients with late cervical lymph node and distant metastases have a poor prognosis. Elective neck dissection and postoperative chemoradiotherapy are considered for these patients, although no clear criteria have been identified for their evaluation. Methods: This retrospective observational study aimed to determine the predictive factors for late cervical lymph node and distant metastases in 102 patients with cT1-2N0 tongue cancer. The data regarding the demographic characteristics, as well as the depth of invasion, tumor budding, histological grade, and tumor–stromal ratio, among other things, were extracted from medical records. Results: We found that the potential lymph node metastasis rate was 27.5%. The significant clinical predictors of late cervical lymph node metastasis were the tumor thickness and endophytic growth pattern and the significant histopathological factors were poorly and moderately differentiated tumors and ≥3 tumor buds. In addition, the prognostic factors for distant metastasis included ≥4 lymph node metastases, ≥7 tumor budding, and moderate and poor tumor differentiation. Conclusions: The usefulness of tumor budding as a predictor of metastasis for tongue cancer was suggested. The findings of this study can help establish the criteria for evaluating the metastasis risk and prognosis of patients with tongue cancers. Full article
(This article belongs to the Special Issue Combination Therapy for Oral Cancer: Current Trends and Challenges)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop